News Swiss biotech Noema raises $112m for Roche castoffs Cash will fund mid-stage trials in epilepsy, trigeminal neuralgia, and other CNS conditions.
News NICE recommends cannabinoid med for severe epilepsy Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received
News Wales is first UK country to fund GW's Epidyolex for tuberou... Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by
News Swiss start-up Noema raises $59m to develop neurology drugs ... Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
